SeanMDonahoeMDFACC

Clinical Trials

• Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin Start of enrollment: 2010 Oct 01

  Completed

  Phase 3

• REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification Start of enrollment: 2011 Jun 01

  Active, not recruiting

  Phase 3

• A Study to Learn How Well the Study Treatment Asundexian Works and How Safe it is Compared to Apixaban to Prevent Stroke or Systemic Embolism in People With Irregular and Often Rapid Heartbeat (Atrial Fibrillation), and at Risk for Stroke Start of enrollment: 2022 Dec 05

  Terminated

  Phase 3

• Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial Start of enrollment: 2022 Dec 14

  Active, not recruiting

  Phase 3

• A Randomized Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Cardiovascular Disease Start of enrollment: 2018 Oct 30

  Active, not recruiting

  Phase 3

• Safety Study of Etripamil Nasal Spray for Patients With Paroxysmal Supraventricular Tachycardia. NODE-303 Start of enrollment: 2019 Sep 23

  Completed

  Phase 3

• EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced) Start of enrollment: 2017 Mar 06

  Completed

  Phase 3

• EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved) Start of enrollment: 2017 Mar 02

  Completed

  Phase 3

• Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD Start of enrollment: 2019 Dec 12

  Active, not recruiting

  Phase 3

• Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone on Morbidity (Events Indicating Disease Worsening) & Mortality (Death Rate) in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40% Start of enrollment: 2020 Sep 14

  Active, not recruiting

  Phase 3

• Evaluation of Major Cardiovascular Events in Participants With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo Start of enrollment: 2016 Dec 22

  Completed

  Phase 3

• A Cross-sectional Study of Lipoprotein(a) Levels in Patients With Documented History of Atherosclerotic Cardiovascular Disease (ASCVD) Start of enrollment: 2022 Apr 19

  Completed

  Not Applicable

• A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors Start of enrollment: 2014 Jan 24

  Completed

  Phase 4

• Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events Start of enrollment: 2013 Apr 25

  Completed

  Phase 3

• A Study of Evacetrapib in High-Risk Vascular Disease Start of enrollment: 2012 Oct 01

  Terminated

  Phase 3

• Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke Start of enrollment: 2019 Jun 11

  Active, not recruiting

  Phase 3

• Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia Start of enrollment: 2014 Oct 30

  Completed

  Phase 3

• Join now to see all